Impact du choix d'un antiagrégant plaquettaire dans l'artériopathie oblitérante des membres inférieurs sur les pertes de chances et sur les coûts médicaux
- 28 February 2007
- journal article
- Published by Elsevier in Journal des Maladies Vasculaires
- Vol. 32 (1) , 8-14
- https://doi.org/10.1016/j.jmv.2006.12.002
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Aspirin in peripheral arterial disease: breakthrough or pitfall?Vasa, 2006
- Prévention des évènements ischémiques majeurs au cours de l’artériopathie oblitérante des membres inférieurs : l’aspirine a-t-elle un rôle ?Journal des Maladies Vasculaires, 2006
- Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevationAmerican Heart Journal, 2006
- Long-Term Cost Effectiveness of Early and Sustained Dual Oral Antiplatelet Therapy With Clopidogrel Given for Up to One Year After Percutaneous Coronary InterventionJournal of the American College of Cardiology, 2005
- The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE studyEuropean Journal of Preventive Cardiology, 2004
- Estimating Survival for Cost-Effectiveness Analyses: A Case Study in AtherothrombosisValue in Health, 2004
- Critical Issues in Peripheral Arterial Disease Detection and ManagementA Call to ActionArchives of internal medicine (1960), 2003
- EPIDEMIOLOGIC DATA IN CLINICAL PRACTICEJournal of the American Geriatrics Society, 2000
- Diagnosis and Treatment of Chronic Arterial Insufficiency of the Lower Extremities: A Critical ReviewCirculation, 1996
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)The Lancet, 1996